U.S. Markets open in 3 hrs 18 mins
WEF 2022

Yahoo Finance is in Davos! Get the latest updates here

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
66.71-1.17 (-1.72%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close67.88
Bid67.00 x 800
Ask99.00 x 900
Day's Range64.35 - 69.85
52 Week Range52.33 - 126.00
Avg. Volume190,798
Market Cap1.141B
Beta (5Y Monthly)1.09
PE Ratio (TTM)N/A
EPS (TTM)-14.65
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est161.67
  • GlobeNewswire

    Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

    CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming investor conferences: H.C. Wainwright Global Life Sciences Conference Fireside chat at 7:00 AM ET on Tuesday, May 24, 2022. UBS Global Healthcare Conference Fireside chat at 8:30 AM ET on Tuesday, May 24, 2022. The pres

  • Simply Wall St.

    We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results

    MAESTRO-NAFLD-1 late-breaker and three other Madrigal abstracts accepted for oral presentation at the EASL International Liver Congress™Data from the Phase 3 MAESTRO-NAFLD-1 study continue to reinforce the safety and efficacy profiles of resmetiromMadrigal remains on track to disclose topline data from MAESTRO-NASH in the fourth quarter and anticipates filing for accelerated approval under Subpart H next yearPlanned MAESTRO-NASH Outcomes trial, a non-invasive Phase 3 study designed to accelerate